| abstract |
The present disclosure describes high concentration liquid formulations of therapeutically active antigen binding proteins, such as monoclonal antibodies. In addition to the antigen binding protein, such a formulation comprises at least 80mM of a buffer and at least 80mM of a stabilizing agent. In addition, the disclosure relates to pharmaceutical formulations of anti-IL-17C antibodies, and provides methods of making and using such formulations. |